A post hoc analysis of BLISS-LN found Belimumab plus mycophenolate mofetil improves kidney outcomes versus placebo plus mycophenolate mofetil in active lupus nephritis - PubMed
3 hours ago
- #belimumab
- #BLISS-LN
- #lupus nephritis
- Post hoc analysis of BLISS-LN shows belimumab plus mycophenolate mofetil improves kidney outcomes in active lupus nephritis compared to placebo plus mycophenolate mofetil.
- The study focused on patients with proliferative or proliferative plus membranous lupus nephritis receiving mycophenolate mofetil-based therapy, aligning with other phase 3 trial designs.
- Belimumab demonstrated greater treatment differences for complete renal response, primary efficacy renal response, and eGFR slope in the mycophenolate mofetil subgroup versus the overall BLISS-LN population.
- Safety outcomes were consistent with belimumab's known profile, with fewer serious adverse events reported for belimumab compared to placebo in the subgroup.